BET201-01

N/A

Report date: 2025/02/20 16:25:11

Base Information

Drug NameBET201-01
Drug Alias NameBET201-01BET-201-01
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Single-domain antibody (Nanobody)
Mechanisms of ActionClaudin-18 splice variant 2 antagonistsProgrammed death-ligand 1 antagonists
TargetsClaudin-18 splice variant 2Programmed death-ligand 1
Therapy Area/IndicationsPancreatic NeoplasmsStomach Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesShandong Bangentai Biomedical Tech Group Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShandong Bangentai Biomedical Tech Group Co Ltd
Inactive CompaniesN/A
Active IndicationsPancreatic NeoplasmsStomach Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A